Get the Stockscreener App
15.55
6.21%
-1.03
After Hours:
15.55
Oruka Therapeutics Inc stock is traded at $15.55, with a volume of 1.17M.
It is down -6.21% in the last 24 hours and up +6.80% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$16.58
Open:
$16.62
24h Volume:
1.17M
Relative Volume:
4.61
Market Cap:
$582.36M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.97%
1M Performance:
+6.80%
6M Performance:
+33.71%
1Y Performance:
-37.35%
1-Day Range:
$15.25
$16.62
1-Week Range:
$14.66
$18.50
52-Week Range:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
15.55 | 620.93M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Short Squeeze: Will Generation Income Properties Inc. Equity Warrant announce a stock splitWeekly Trade Recap & AI Optimized Trading Strategy Guides - khodrobank.com
Options Flow: Will Oruka Therapeutics Inc outperform tech stocksJuly 2025 Decliners & Expert Verified Movement Alerts - khodrobank.com
Should you wait for a breakout in Oruka Therapeutics Inc.Exit Point & Daily Stock Trend Reports - newser.com
Will Oruka Therapeutics Inc. bounce back from current supportTrade Signal Summary & Free Accurate Trade Setup Notifications - newser.com
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street Zen - MarketBeat
Visual analytics tools that track Oruka Therapeutics Inc. performanceJuly 2025 Sentiment & Accurate Buy Signal Notifications - newser.com
Is Oruka Therapeutics Inc. forming a bottoming base2025 EndofYear Setup & Free Expert Verified Stock Movement Alerts - newser.com
Analyzing Oruka Therapeutics Inc. with multi timeframe chartsTrade Entry Report & Consistent Profit Alerts - newser.com
Jobs Data: Can Oruka Therapeutics Inc deliver consistent EPS growthWeekly Market Summary & Daily Technical Stock Forecast Reports - khodrobank.com
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Is Oruka Therapeutics Inc. stock bottoming outPortfolio Profit Report & Stock Market Timing Techniques - newser.com
Will Oruka Therapeutics Inc. continue its uptrend2025 Key Highlights & Consistent Return Investment Signals - newser.com
Short Covering: How does Oruka Therapeutics Inc compare to its peersTrade Analysis Summary & Accurate Entry/Exit Alerts - khodrobank.com
Candlestick signals on Oruka Therapeutics Inc. stock today2025 Dividend Review & Short-Term High Return Ideas - newser.com
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap UpStill a Buy? - MarketBeat
IPO Launch: Is now the right time to enter NWBITrade Risk Assessment & Capital Protection Trading Alerts - خودرو بانک
Quantitative breakdown of Oruka Therapeutics Inc. recent moveWeekly Stock Recap & Weekly Return Optimization Alerts - newser.com
Volume Recap: Is Oruka Therapeutics Inc.’s growth already priced inTrade Analysis Report & Risk Adjusted Swing Trade Ideas - khodrobank.com
Aug Weekly: Will Oruka Therapeutics Inc benefit from AI trendsQuarterly Market Review & High Win Rate Trade Alerts - khodrobank.com
Oruka Therapeutics stock price target raised to $56 at BTIG on promising drug data - Investing.com Canada
Volatility clustering patterns for Oruka Therapeutics Inc.Market Trend Report & Consistent Income Trade Ideas - newser.com
Oruka Therapeutics, Regeneron, natgas companies - TradingView
Oruka reveals $180M financing and late breaking psoriasis data - The Pharma Letter
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday - Benzinga
Oruka Therapeutics jumps after positive early-stage study data for psoriasis drug - TradingView
Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker - inkl
Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial - Seeking Alpha
Oruka Therapeutics stock surges after positive Phase 1 results By Investing.com - Investing.com Canada
Oruka Therapeutics raises $180 million in private placement By Investing.com - Investing.com Canada
Oruka Therapeutics Says ORKA-001 Interim Early-Stage Data Supports Extended Dosing Intervals; Plans $180 Million Private Placement - MarketScreener
Oruka’s IL-23 antibody shows potential for once-yearly psoriasis dosing - Investing.com Nigeria
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 5.4%Should You Sell? - MarketBeat
Oruka Therapeutics, Inc. announced that it expects to receive $179.999998 million in funding from a group of investors - MarketScreener
Oruka Therapeutics raises $180 million in private placement - Investing.com
Relative strength of Oruka Therapeutics Inc. in sector analysis2025 Performance Recap & AI Powered Buy and Sell Recommendations - newser.com
Oruka Therapeutics Reports Positive Interim Data From Phase 1 Study Of ORKA-001 - Nasdaq
Oruka Therapeutics Announces $180 Million Private Placement - GlobeNewswire
Oruka Therapeutics announces positive interim phase 1 results for ORKA-001 - MarketScreener
$180 Million Financing: Biotech Oruka Therapeutics Attracts Elite Healthcare Investors for Skin Disease Programs - Stock Titan
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 - GlobeNewswire
100-Day Half-Life, 3x Longer Than Current Drugs: Oruka's ORKA-001 Could Enable Once-Yearly Psoriasis Treatment - Stock Titan
Gainers Report: How does Oruka Therapeutics Inc compare to its peersMarket Activity Summary & Free Expert Verified Stock Movement Alerts - خودرو بانک
Published on: 2025-09-16 19:43:47 - khodrobank.com
Stock Recap: What’s the profit margin of BZUNEarnings Summary Report & Weekly Sector Rotation Insights - خودرو بانک
Is Oruka Therapeutics Inc. stock poised for growthRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Aug Update: Is Contineum Therapeutics Inc. a defensive stockJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - khodrobank.com
Sentiment Recap: Can Oruka Therapeutics Inc. expand into new marketsEarnings Overview Summary & AI Powered Trade Plan Recommendations - khodrobank.com
Sentiment Watch: Will Oruka Therapeutics Inc stock hit new highs in YEARWeekly Profit Recap & Low Volatility Stock Recommendations - خودرو بانک
Aug Decliners: What is Oruka Therapeutics Incs book value per shareDividend Hike & Low Drawdown Investment Ideas - khodrobank.com
Portfolio Recap: Is Lion Group Holding Ltd Equity Warrant forming a breakout pattern2025 Market WrapUp & Reliable Price Action Trade Plans - خودرو بانک
Analyzing net buyer seller activity in Oruka Therapeutics Inc.2025 Technical Overview & Stock Timing and Entry Methods - newser.com
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
11.63 |
14,950 |
173,868 |
4,059,634 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
11.86 |
8,971 |
106,396 |
4,044,684 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
10.95 |
9,593 |
105,043 |
4,035,713 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
10.90 |
574 |
6,257 |
4,026,120 |
1.43%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):